|
🐜
|
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
44 auth.
David P Gillessen,
Silke Gilson,
C. Jones,
Robert J Langley,
R. Malik,
C. Parker,
N. James,
C. Brawley,
N. Clarke,
A. Hoyle,
Adnan Ali,
A. Ritchie,
G. Attard,
S. Chowdhury,
W. Cross,
...
D. Dearnaley,
S. Gillessen,
C. Gilson,
Robert J. Jones,
R. Langley,
Z. Malik,
M. Mason,
D. Matheson,
R. Millman,
J. Russell,
G. Thalmann,
C. Amos,
R. Alonzi,
A. Bahl,
A. Birtle,
O. Din,
H. Douis,
C. Eswar,
J. Gale,
M. Gannon,
S. Jonnada,
S. Khaksar,
J. Lester,
J. O’Sullivan,
O. Parikh,
I. Pedley,
D. Pudney,
D. Sheehan,
N. Srihari
|
9 |
2018 |
9
🐜
|
|
🐜
|
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
55 auth.
M. Sydes,
M. Spears,
M. Mason,
N. Clarke,
D. Dearnaley,
J. D. Bono,
G. Attard,
S. Chowdhury,
W. Cross,
S. Gillessen,
S. Gillessen,
Z. Malik,
Robert J. Jones,
Robert Jones,
C. Parker,
...
A. Ritchie,
J. Russell,
J. Russell,
R. Millman,
D. Matheson,
C. Amos,
C. Gilson,
A. Birtle,
S. Brock,
L. Capaldi,
P. Chakraborti,
A. Choudhury,
A. Choudhury,
L. Evans,
D. Ford,
J. Gale,
S. Gibbs,
D. Gilbert,
R. Hughes,
D. McLaren,
J. Lester,
A. Nikapota,
J. O’Sullivan,
J. O’Sullivan,
O. Parikh,
C. Peedell,
A. Protheroe,
S. Rudman,
R. Shaffer,
D. Sheehan,
M. Simms,
N. Srihari,
R. Strebel,
S. Sundar,
S. Tolan,
D. Tsang,
M. Varughese,
J. Wagstaff,
M. Parmar,
N. James
|
7 |
2018 |
7
🐜
|
|
🐜
|
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
154 auth.
G. Attard,
L. Murphy,
N. Clarke,
W. Cross,
Robert J. Jones,
C. Parker,
S. Gillessen,
A. Cook,
C. Brawley,
C. Amos,
N. Atako,
C. Pugh,
Michelle M. C. Buckner,
S. Chowdhury,
Z. Malik,
...
J. Russell,
C. Gilson,
H. Rush,
J. Bowen,
A. Lydon,
I. Pedley,
J. O’Sullivan,
A. Birtle,
J. Gale,
N. Srihari,
Carys W Thomas,
J. Tanguay,
J. Wagstaff,
P. Das,
Emma Gray,
Mymoona Alzoueb,
O. Parikh,
A. Robinson,
I. Syndikus,
J. Wylie,
A. Zarkar,
G. Thalmann,
J. Bono,
D. Dearnaley,
M. Mason,
D. Gilbert,
R. Langley,
R. Millman,
D. Matheson,
M. Sydes,
L. Brown,
M. Parmar,
Nicholas D. James,
E. Jones,
K. Hyde,
H. Glen,
S. Needleman,
U. McGovern,
D. Sheehan,
S. Paisey,
R. Shaffer,
M. Beresford,
E. Porfiri,
D. Fackrell,
Ling-hui Lee,
T. Sreenivasan,
S. Brock,
Simon Brown,
A. Bahl,
Mike Smith-Howell,
C. Woodward,
M. Phan,
D. Mazhar,
K. Narahari,
F. Douglas,
Ajay Kumar,
A. Hamid,
A. Ibrahim,
D. Muthukumar,
M. Simms,
J. Worlding,
A. Tran,
M. Kagzi,
C. Pezaro,
Virgil Sivoglo,
B. Masters,
Pek Keng-Koh,
C. Manetta,
D. McLaren,
Nishi Gupta,
S. Boussios,
H. Taylor,
J. Graham,
C. Perna,
L. Melcher,
Warren C. Grant,
A. Sabharwal,
U. Hofmann,
R. Dealey,
N. McPhail,
R. Brierly,
L. Capaldi,
N. Sidek,
P. Whelan,
P. Robson,
A. Falconer,
S. Rudman,
S. Vivekanandan,
Vinod Mullessey,
M. Vilarino-Varela,
V. Khoo,
K. Tipples,
M. Afshar,
P. Brulinski,
V. Sangar,
C. Peedell,
A. Azzabi,
P. Hoskin,
Viwod Mullassery,
S. Sundar,
Yakhub Khan,
R. Conroy,
A. Protheroe,
J. Carser,
P. Rogers,
K. Tarver,
S. Gibbs,
M. M. Khan,
M. Hingorani,
S. Crabb,
M. Alameddine,
N. Bhalla,
R. Hughes,
J. Logue,
D. Leaning,
Salil Vengalil,
D. Ford,
G. Walker,
A. Shaheen,
Omar Khan,
Andrew Chan,
I. Ahmed,
S. Hilman,
I. Sayers,
A. Nikapota,
D. Bloomfield,
T. Porter,
J. Joseph,
C. Rentsch,
R. P. Mestre,
E. Roggero,
Jörg Beyer,
M. Borner,
R. Strebel,
D. Berthold,
D. Engeler,
Hubert John,
Razvan Popescu,
Donat Durr
|
7 |
2021 |
7
🐜
|
|
🐜
|
Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)
14 auth.
R. Huddart,
E. Hall,
S. Hussain,
P. Jenkins,
C. Rawlings,
Jean Tremlett,
M. Crundwell,
F. Adab,
D. Sheehan,
I. Syndikus,
...
C. Hendron,
Rebecca Lewis,
R. Waters,
N. James
|
6 |
2013 |
6
🐜
|
|
🐜
|
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
19 auth.
Nicholas D. James,
M. Sydes,
M. Mason,
N. Clarke,
John Anderson,
D. Dearnaley,
J. Dwyer,
G. Jovic,
A. Ritchie,
J. Russell,
...
Karen Sanders,
G. Thalmann,
G. Bertelli,
A. Birtle,
J. O’Sullivan,
A. Protheroe,
D. Sheehan,
N. Srihari,
M. Parmar
|
6 |
2012 |
6
🐜
|
|
🐜
|
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
15 auth.
E. Hall,
S. Hussain,
N. Porta,
Rebecca Lewis,
M. Crundwell,
P. Jenkins,
C. Rawlings,
Jean Tremlett,
T. Sreenivasan,
J. Wallace,
...
I. Syndikus,
D. Sheehan,
A. Lydon,
R. Huddart,
N. James
|
6 |
2022 |
6
🐜
|
|
🐜
|
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
56 auth.
Nicholas D. James,
Noel W. Clarke,
A. Cook,
Adnan Ali,
A. Hoyle,
Gerhardt Attard,
C. Brawley,
Simon Chowdhury,
W. Cross,
D. Dearnaley,
J. S. Bono,
C. Diaz-Montana,
D. Gilbert,
S. Gillessen,
C. Gilson,
...
Rob J Jones,
Ruth E Langley,
Zafar Malik,
D. Matheson,
R. Millman,
Chris C Parker,
Cheryl A Pugh,
H. Rush,
J. Russell,
Dominik R. Berthold,
Michelle L. Buckner,
Malcolm D. Mason,
Alastair WS Ritchie,
A. Birtle,
S. Brock,
Prantik Das,
Dan Ford,
Joanna Gale,
Warren Grant,
E. Gray,
Peter J Hoskin,
M. M. Khan,
C. Manetta,
N. McPhail,
Joe M O'Sullivan,
O. Parikh,
Carla Perna,
C. Pezaro,
A. Protheroe,
A. Robinson,
S. Rudman,
D. Sheehan,
N. Srihari,
I. Syndikus,
Jacob S Tanguay,
Carys W. Thomas,
Salil Vengalil,
John Wagstaff,
James Wylie,
Mahesh K. B. Parmar,
M. Sydes
|
5 |
2022 |
5
🐜
|
|
🐜
|
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
98 auth.
Janet E. Brown,
Kara-Louise Royle,
W. Gregory,
C. Ralph,
A. Maraveyas,
O. Din,
T. Eisen,
P. Nathan,
T. Powles,
R. Griffiths,
Robert Jones,
N. Vasudev,
M. Wheater,
A. Hamid,
T. Waddell,
...
R. McMenemin,
P. Patel,
J. Larkin,
G. Faust,
Adam Martin,
J. Swain,
J. Bestall,
Christopher McCabe,
D. Meads,
V. Goh,
Tze Min Wah,
Julia M. Brown,
J. Hewison,
P. Selby,
F. Collinson,
J. Carser,
G. Srinivasan,
Fiona Thistlewaite,
A. Azzabi,
M. Beresford,
D. Farrugia,
M. Decatris,
Carys W Thomas,
J. Gale,
J. Mcaleer,
A. Clayton,
E. Boleti,
T. Geldart,
S. Sundar,
J. Lester,
N. Palaniappan,
M. Hingorani,
K. Rehman,
Mohammad Khan,
N. Sarwar,
Janine Graham,
A. Thomson,
N. Srihari,
D. Sheehan,
R. Srinivasan,
O. Khan,
Andrew Stockdale Jane Worlding,
S. Boussios,
N. Stuart,
C. MacDonald-Smith,
F. Danwata,
D. McLaren,
A. Sundaramurthy,
A. Lydon,
S. Beesley,
K. Lees,
M. Varughese,
Emma Gray,
Angela Scott,
M. Baxter,
A. Mullard,
P. Innominato,
G. Kapur,
Ajay Kumar,
N. Charnley,
C. Manetta,
P. Chakraborti,
P. Das,
S. Rudman,
H. Taylor,
C. Mikropoulos,
M. Highley,
D. Muthukumar,
A. Zarkar,
R. Vergis,
S. Sriprasad,
P. Brulinski,
A. Clarke,
R. Osbourne,
M. Harvey,
Renata Dega,
G. Sparrow,
U. Barthakur,
E. Beaumont,
A. Michael,
E. Porfiri,
F. Azam,
Ravi Kodavtiganti
|
5 |
2023 |
5
🐜
|
|
🐜
|
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
159 auth.
G. Attard,
L. Murphy,
N. Clarke,
A. Sachdeva,
Craig Jones,
A. Hoyle,
W. Cross,
Robert J. Jones,
Christopher C. Parker,
S. Gillessen,
A. Cook,
C. Brawley,
C. Gilson,
H. Rush,
H. Abdel-Aty,
...
C. Amos,
C. Murphy,
S. Chowdhury,
Z. Malik,
J. Russell,
Nazia Parkar,
C. Pugh,
C. Diaz-Montana,
C. Pezaro,
W. Grant,
H. Saxby,
I. Pedley,
J. O’Sullivan,
A. Birtle,
J. Gale,
N. Srihari,
Carys W Thomas,
J. Tanguay,
J. Wagstaff,
P. Das,
E. Gray,
M. Alzouebi,
O. Parikh,
A. Robinson,
A. Montazeri,
J. Wylie,
A. Zarkar,
R. Cathomas,
Michael D Brown,
Y. Jain,
D. Dearnaley,
M. Mason,
D. Gilbert,
R. Langley,
R. Millman,
D. Matheson,
M. Sydes,
L. Brown,
M. Parmar,
Nicholas D. James,
Elin Jones,
K. Hyde,
Hilary Glen,
Sarah Needleman,
U. McGovern,
D. Sheehan,
S. Paisey,
Richard Shaffer,
Mark Beresford,
E. Porfiri,
D. Fackrell,
Ling Lee,
T. Sreenivasan,
S. Brock,
Simon Brown,
Amit Bahl,
Mike Smith-Howell,
C. Woodward,
M. Phan,
Danish Mazhar,
K. Narahari,
Fiona Douglas,
Anil Kumar,
Abdel Hamid,
A. Ibrahim,
D. Muthukumar,
M. Simms,
J. Worlding,
Anna Tran,
M. Kagzi,
Virgil Sivoglo,
Benjamin Masters,
Pek Keng-Koh,
C. Manetta,
Duncan McLaren,
Nishi Gupta,
S. Boussios,
Henry Taylor,
John Graham,
Carla Perna,
L. Melcher,
A. Sabharwal,
U. Hofmann,
R. Dealey,
N. McPhail,
R. Brierly,
L. Capaldi,
N. Sidek,
Peter Whelan,
Peter Robson,
A. Falconer,
S. Rudman,
Sindu Vivekanandan,
Vinod Mullessey,
M. Vilarino-Varela,
Vincent Khoo,
K. Tipples,
M. Afshar,
P. Brulinski,
Vijay Sangar,
Clive Peedell,
A. Azzabi,
Peter J Hoskin,
Viwod Mullassery,
Santhanam Sundar,
Yakhub Khan,
R. Conroy,
A. Protheroe,
J. Carser,
Paul Rogers,
K. Tarver,
S. Gibbs,
M. M. Khan,
Mohan Hingorani,
S. Crabb,
M. Alameddine,
Neeraj Bhalla,
Robert Hughes,
J. Logue,
D. Leaning,
Salil Vengalil,
Dan Ford,
G. Walker,
Ahmed Shaheen,
Omar Khan,
Andrew Chan,
Imtiaz Ahmed,
S. Hilman,
I. Sayers,
A. Nikapota,
D. Bloomfield,
Tim Porter,
Joji Joseph,
Cyrill A. Rentsch,
R. Pereira Mestre,
Enrico Roggero,
Jörg Beyer,
Markus Borner,
R. Strebel,
Dominik R. Berthold,
Daniel Engeler,
Hubert John,
Razvan Popescu,
Donat Durr
|
5 |
2023 |
5
🐜
|
|
🐜
|
LBA31_PRAdding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)
20 auth.
M. Sydes,
M. Mason,
M. Spears,
N. Clarke,
D. Dearnaley,
A. Ritchie,
M. Russell,
C. Gilson,
Robert J. Jones,
J. Bono,
...
S. Gillessen,
R. Millman,
S. Tolan,
J. Wagstaff,
S. Chowdhury,
J. Lester,
D. Sheehan,
J. Gale,
M. Parmar,
N. James
|
4 |
2017 |
4
🐜
|
